Emergent BioSolutions (EBS) Scheduled to Post Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Emergent BioSolutions to post earnings of $0.49 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The firm had revenue of $254.70 million for the quarter, compared to analysts’ expectations of $199.47 million. During the same quarter last year, the firm posted ($1.06) earnings per share. On average, analysts expect Emergent BioSolutions to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Emergent BioSolutions Stock Up 0.2 %

Shares of EBS stock opened at $8.79 on Tuesday. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The company has a 50-day simple moving average of $8.32 and a two-hundred day simple moving average of $7.59.

Analyst Ratings Changes

A number of brokerages recently commented on EBS. Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of Emergent BioSolutions in a research report on Friday, August 16th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.